The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Influence of Cholesterol on the Association of Plasma Proteins with Liposomes
Abstract
The in vivo association of blood proteins with large unilamellar liposomes composed of saturated phosphatidylcholines was analyzed to determine the effect of membrane fluidity and hydrocarbon chain length on liposome-plasma protein interactions and liposome clearance. Liposomes composed of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), and diarachidoylphosphatidylcholine (DAPC) were administered via the lateral tail vein of CD-1 mice and were subsequently isolated from the blood at 2 min postinjection. The protein binding ability (PB, grams of protein bound per mole total lipid) of the liposomes was quantified and related to their circulation half-lives. Liposomes composed of long-chain saturated phospholipids that exist in the gel (frozen) state at 39 degrees C (DPPC,DSPC and DAPC) bound large quantities of blood proteins, in excess of 48 g of protein per mole total lipid, and were found to be rapidly cleared from the circulation. The incorporation of cholesterol into DSPC liposomes resulted in significantly decreased PB values and enhanced circulation lifetimes for this lipid system. This cholesterol effect plateaued at 30 mol % cholesterol, corresponding to the loss of the gel-liquid crystalline phase transition, and resulted in PB values of 23-28 grams of protein per mole of total lipid. The types of blood proteins binding to DSPC liposomes were not significantly altered by the inclusion of cholesterol. This is the first demonstration of rapid clearance of neutral large unilamellar liposomes having high levels of bound protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physical properties of the fluid lipid-bilayer component of cell membranes: a perspective
Bloom, M., Evans, E., & Mouritsen, O. G. (1991) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500003735 · Cited by 872
Kirby, C., Clarke, J., & Gregoriadis, G. (1980) · Biochemical Journal · doi:10.1042/bj1860591 · Cited by 592
Chonn, A., Semple, S. C., & Cullis, P. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37026-7 · Cited by 460
Self-citationLiposomes as drug carriers : recent trends and progress
Gregoriadis, G. (1988) · Wiley eBooks · Cited by 283
Liposomes as Drug Carriers: Recent Trends and Progress
Duncan, R., & Bhakoo, M. (1989) · Vaccine · doi:10.1016/0264-410x(89)90036-4 · Cited by 184
Gregoriadis, G., & Senior, J. H. (1980) · FEBS Letters · doi:10.1016/0014-5793(80)80994-x · Cited by 135
Biological stability of [3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat
Stein, Y., Halperin, G., & Stein, O. T. (1980) · FEBS Letters · doi:10.1016/0014-5793(80)80771-x · Cited by 87
Cited by
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Self-citationOptimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114416 · Cited by 1,185
Ogris, M., Brunner, S., Schüller, S., Kircheis, R., & Wagner, E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300900 · Cited by 1,178
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 877
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Current status of pH-sensitive liposomes in drug delivery
Drummond, D. C., Zignani, M., & Leroux, J.-C. (2000) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00011-4 · Cited by 477
Semple, S. C., Chonn, A., & Cullis, P. R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00128-2 · Cited by 402
Self-citationMohammed, A. R., Weston, N., Coombes, A. G. A., Fitzgerald, M., & Perrie, Y. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.07.010 · Cited by 386
Dash, P. R., Read, M. L., Barrett, L. B., Wolfert, M. A., & Seymour, L. W. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300843 · Cited by 386
Characterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene delivery
Li, S., Rizzo, M., Bhattacharya, S., & Huang, L. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300683 · Cited by 369
Gene delivery with synthetic (non viral) carriers
Brown, M. D., Schätzlein, A. G., & Uchegbu, I. F. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00861-4 · Cited by 367
Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R. F., Dawson, K., & Kostarelos, K. (2015) · ACS Nano · doi:10.1021/acsnano.5b03300 · Cited by 358
Dos Santos, N., Allen, C., Doppen, A.-M., Anantha, M., Cox, K. A. K., Gallagher, R. C., Karlsson, G., Edwards, K., Kenner, G., Samuels, L., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.12.013 · Cited by 341
Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers
Salmaso, S., & Caliceti, P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/374252 · Cited by 340
Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M. (2018) · Small Methods · doi:10.1002/smtd.201700375 · Cited by 332
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Zelphati, O., Uyechi, L. S., Barron, L. G., & Szoka, F. C. (1998) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(97)00169-0 · Cited by 310
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00366 · Cited by 299
Self-citationPharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., & Kirpotin, D. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21358 · Cited by 289
Anderson, M., & Omri, A. (2004) · Drug Delivery · doi:10.1080/10717540490265243 · Cited by 286
How to Stabilize Phospholipid Liposomes (Using Nanoparticles)
Zhang, L., & Granick, S. (2006) · Nano Letters · doi:10.1021/nl052455y · Cited by 278
Boissenot, T., Bordat, A., Fattal, E., & Tsapis, N. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.026 · Cited by 264
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 264
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 260
Synthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Metadata
- Authors
- Semple, S. C., Chonn, A., & Cullis, P. R.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1996-01-01
- Volume
- 35
- Issue
- 8
- Pages
- 2521-2525
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2002059065
- Cited by
- 291
- References
- 7
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.